Macrogenics (MGNX) Cash & Equivalents (2012 - 2026)

Macrogenics (MGNX) has reported Cash & Equivalents for 15 consecutive years, with $66.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 54.31% year-over-year to $66.5 million; the TTM figure through Mar 2026 stood at $66.5 million (down 54.31% YoY), while the FY2025 annual figure was $57.2 million, down 68.71% from the prior year.
• Cash & Equivalents climbed to $66.5 million in Q1 2026 per MGNX's latest filing, from $57.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $224.3 million in Q1 2023 and bottomed at $21.5 million in Q2 2022.
• Historically, Cash & Equivalents has averaged $105.4 million across 5 years, with a median of $89.9 million in 2023.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 88.64% — and 2023, when it surged 406.58%.
• Macrogenics' Cash & Equivalents stood at $108.9 million in 2022, then decreased by 7.28% to $101.0 million in 2023, then surged by 81.11% to $182.8 million in 2024, then tumbled by 68.71% to $57.2 million in 2025, then gained by 16.25% to $66.5 million in 2026.
• Business Quant data shows MGNX's Cash & Equivalents at $66.5 million in Q1 2026, $57.2 million in Q4 2025, and $80.1 million in Q3 2025.